News and Media

MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study

MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study

Canton, Mich. (July 10, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today its integrated support for Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH). MMS supported data aspects for Gemphire in achieving its primary endpoint…

MMS Hires CRO Leader Lisa James as Director of Business Operations and Client Relations

MMS Hires CRO Leader Lisa James as Director of Business Operations and Client Relations

Durham, N.C. (June 13, 2018) – MMS Holdings Inc. (MMS) – a leading global clinical research organization – announced today that Lisa James has joined as Director, Business Operations and Client Relations. James brings a depth of industry and business experience, having most recently held the position as Director of Corporate Operations at Health Decisions, Inc.

MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period

MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period

Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.

MMS Responds to Rapid Growth in North Carolina with Key Hires

MMS Responds to Rapid Growth in North Carolina with Key Hires

Posted April 19, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today the hiring of John Mitcheson as Senior Proposal Development Manager and Joy Willard, RN, BSN, PMP as Senior Project Manager in response to double digit company growth in North Carolina for the past three years.

MMS reaches an employee training milestone of 700 pharma industry courses

MMS reaches an employee training milestone of 700 pharma industry courses

Posted April 13, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This platform offers education to all MMS colleagues across North America, Europe, India, and South Africa in a variety of formats from instructor led to self-directed sessions.

MMS Selected by Paratek to Support its NDA Submissions for Omadacycline

MMS Selected by Paratek to Support its NDA Submissions for Omadacycline

Poster November 15, 2017
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Since its selection in June, MMS has been assisting in drafting, assembling and publishing the clinical components of the omadacycline NDAs for the U.S. Food and Drug Administration (FDA) in acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Media Contact

Don McLean, MBA
Sr. Manager, Global Marketing & Communications
6880 Commerce Blvd.
Canton, MI 48187 USA
734. 245.0165
media@mmsholdings.com

 

6880 Commerce Blvd.
Canton, MI 48187 USA
734.245.0310 T
734.245.0320 F

Email Us

FacebookLinkedIn

Learn more about working with MMS

14 + 6 =

© MMS Holdings Inc. All rights reserved. Privacy Policy